MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation

Maria E. Figueroa, Lucy Skrabanek, Yushan Li, Anchalee Jiemjit, Tamer E. Fandy, Elisabeth M. Paietta, Hugo Fernandez, Martin S. Tallman, John M. Greally, Hetty Carraway, Jonathan D. Licht, Steven D. Gore, Ari Melnick

Research output: Contribution to journalArticle

241 Citations (Scopus)

Abstract

Increasing evidence shows aberrant hypermethylation of genes occurring in and potentially contributing to pathogenesis of myeloid malignancies. Several of these diseases, such as myelodysplastic syndromes (MDSs), are responsive to DNA methyltransferase inhibitors. To determine the extent of promoter hypermethylation in such tumors, we compared the distribution of DNA methylation of 14 000 promoters in MDS and secondary acute myeloid leukemia (AML) patients enrolled in a phase 1 trial of 5-azacytidine and the histone deacetylase inhibitor entinostat against de novo AML patients and normal CD34+ bone marrow cells. The MDS and secondary AML patients displayed more extensive aberrant DNA methylation involving thousands of genes than did the normal CD34+ bone marrow cells or de novo AML blasts. Aberrant methylation in MDS and secondary AML tended to affect particular chromosomal regions, occurred more frequently in Alupoor genes, and included prominent involvement of genes involved in the WNT and MAPK signaling pathways. DNA methylation was also measured at days 15 and 29 after the first treatment cycle. DNA methylation was reversed at day 15 in a uniform manner throughout the genome, and this effect persisted through day 29, even without continuous administration of the study drugs. This trial was registered at www.clinicaltrials.gov as J0443.

Original languageEnglish (US)
Pages (from-to)3448-3458
Number of pages11
JournalBlood
Volume114
Issue number16
DOIs
StatePublished - 2009

Fingerprint

Myelodysplastic Syndromes
DNA Methylation
Acute Myeloid Leukemia
Genes
Bone Marrow Cells
Bone
Cells
Azacitidine
Histone Deacetylase Inhibitors
Methylation
Methyltransferases
Tumors
Neoplasms
Genome
DNA
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Figueroa, M. E., Skrabanek, L., Li, Y., Jiemjit, A., Fandy, T. E., Paietta, E. M., ... Melnick, A. (2009). MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood, 114(16), 3448-3458. https://doi.org/10.1182/blood-2009-01-200519

MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. / Figueroa, Maria E.; Skrabanek, Lucy; Li, Yushan; Jiemjit, Anchalee; Fandy, Tamer E.; Paietta, Elisabeth M.; Fernandez, Hugo; Tallman, Martin S.; Greally, John M.; Carraway, Hetty; Licht, Jonathan D.; Gore, Steven D.; Melnick, Ari.

In: Blood, Vol. 114, No. 16, 2009, p. 3448-3458.

Research output: Contribution to journalArticle

Figueroa, ME, Skrabanek, L, Li, Y, Jiemjit, A, Fandy, TE, Paietta, EM, Fernandez, H, Tallman, MS, Greally, JM, Carraway, H, Licht, JD, Gore, SD & Melnick, A 2009, 'MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation', Blood, vol. 114, no. 16, pp. 3448-3458. https://doi.org/10.1182/blood-2009-01-200519
Figueroa, Maria E. ; Skrabanek, Lucy ; Li, Yushan ; Jiemjit, Anchalee ; Fandy, Tamer E. ; Paietta, Elisabeth M. ; Fernandez, Hugo ; Tallman, Martin S. ; Greally, John M. ; Carraway, Hetty ; Licht, Jonathan D. ; Gore, Steven D. ; Melnick, Ari. / MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. In: Blood. 2009 ; Vol. 114, No. 16. pp. 3448-3458.
@article{44c922a0df024d22a007415e65467752,
title = "MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation",
abstract = "Increasing evidence shows aberrant hypermethylation of genes occurring in and potentially contributing to pathogenesis of myeloid malignancies. Several of these diseases, such as myelodysplastic syndromes (MDSs), are responsive to DNA methyltransferase inhibitors. To determine the extent of promoter hypermethylation in such tumors, we compared the distribution of DNA methylation of 14 000 promoters in MDS and secondary acute myeloid leukemia (AML) patients enrolled in a phase 1 trial of 5-azacytidine and the histone deacetylase inhibitor entinostat against de novo AML patients and normal CD34+ bone marrow cells. The MDS and secondary AML patients displayed more extensive aberrant DNA methylation involving thousands of genes than did the normal CD34+ bone marrow cells or de novo AML blasts. Aberrant methylation in MDS and secondary AML tended to affect particular chromosomal regions, occurred more frequently in Alupoor genes, and included prominent involvement of genes involved in the WNT and MAPK signaling pathways. DNA methylation was also measured at days 15 and 29 after the first treatment cycle. DNA methylation was reversed at day 15 in a uniform manner throughout the genome, and this effect persisted through day 29, even without continuous administration of the study drugs. This trial was registered at www.clinicaltrials.gov as J0443.",
author = "Figueroa, {Maria E.} and Lucy Skrabanek and Yushan Li and Anchalee Jiemjit and Fandy, {Tamer E.} and Paietta, {Elisabeth M.} and Hugo Fernandez and Tallman, {Martin S.} and Greally, {John M.} and Hetty Carraway and Licht, {Jonathan D.} and Gore, {Steven D.} and Ari Melnick",
year = "2009",
doi = "10.1182/blood-2009-01-200519",
language = "English (US)",
volume = "114",
pages = "3448--3458",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "16",

}

TY - JOUR

T1 - MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation

AU - Figueroa, Maria E.

AU - Skrabanek, Lucy

AU - Li, Yushan

AU - Jiemjit, Anchalee

AU - Fandy, Tamer E.

AU - Paietta, Elisabeth M.

AU - Fernandez, Hugo

AU - Tallman, Martin S.

AU - Greally, John M.

AU - Carraway, Hetty

AU - Licht, Jonathan D.

AU - Gore, Steven D.

AU - Melnick, Ari

PY - 2009

Y1 - 2009

N2 - Increasing evidence shows aberrant hypermethylation of genes occurring in and potentially contributing to pathogenesis of myeloid malignancies. Several of these diseases, such as myelodysplastic syndromes (MDSs), are responsive to DNA methyltransferase inhibitors. To determine the extent of promoter hypermethylation in such tumors, we compared the distribution of DNA methylation of 14 000 promoters in MDS and secondary acute myeloid leukemia (AML) patients enrolled in a phase 1 trial of 5-azacytidine and the histone deacetylase inhibitor entinostat against de novo AML patients and normal CD34+ bone marrow cells. The MDS and secondary AML patients displayed more extensive aberrant DNA methylation involving thousands of genes than did the normal CD34+ bone marrow cells or de novo AML blasts. Aberrant methylation in MDS and secondary AML tended to affect particular chromosomal regions, occurred more frequently in Alupoor genes, and included prominent involvement of genes involved in the WNT and MAPK signaling pathways. DNA methylation was also measured at days 15 and 29 after the first treatment cycle. DNA methylation was reversed at day 15 in a uniform manner throughout the genome, and this effect persisted through day 29, even without continuous administration of the study drugs. This trial was registered at www.clinicaltrials.gov as J0443.

AB - Increasing evidence shows aberrant hypermethylation of genes occurring in and potentially contributing to pathogenesis of myeloid malignancies. Several of these diseases, such as myelodysplastic syndromes (MDSs), are responsive to DNA methyltransferase inhibitors. To determine the extent of promoter hypermethylation in such tumors, we compared the distribution of DNA methylation of 14 000 promoters in MDS and secondary acute myeloid leukemia (AML) patients enrolled in a phase 1 trial of 5-azacytidine and the histone deacetylase inhibitor entinostat against de novo AML patients and normal CD34+ bone marrow cells. The MDS and secondary AML patients displayed more extensive aberrant DNA methylation involving thousands of genes than did the normal CD34+ bone marrow cells or de novo AML blasts. Aberrant methylation in MDS and secondary AML tended to affect particular chromosomal regions, occurred more frequently in Alupoor genes, and included prominent involvement of genes involved in the WNT and MAPK signaling pathways. DNA methylation was also measured at days 15 and 29 after the first treatment cycle. DNA methylation was reversed at day 15 in a uniform manner throughout the genome, and this effect persisted through day 29, even without continuous administration of the study drugs. This trial was registered at www.clinicaltrials.gov as J0443.

UR - http://www.scopus.com/inward/record.url?scp=70350720044&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350720044&partnerID=8YFLogxK

U2 - 10.1182/blood-2009-01-200519

DO - 10.1182/blood-2009-01-200519

M3 - Article

VL - 114

SP - 3448

EP - 3458

JO - Blood

JF - Blood

SN - 0006-4971

IS - 16

ER -